152 results on '"Gross, Andrea M"'
Search Results
2. MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus.
3. Advancing RAS/RASopathy therapies: An NCI‐sponsored intramural and extramural collaboration for the study of RASopathies
4. Pharmacogenetic and clinical predictors of ondansetron failure in a diverse pediatric oncology population
5. Diagnosis and Management of Benign Nerve Sheath Tumors in NF1: Evolution from Plexiform to Atypical Neurofibroma and Novel Treatment Approaches
6. Early detection of malignant and pre-malignant peripheral nerve tumors using cell-free DNA fragmentomics
7. A molecular basis for neurofibroma-associated skeletal manifestations in NF1
8. Current status of MEK inhibitors in the treatment of plexiform neurofibromas
9. Development and pilot validation of a novel disfigurement severity scale for plexiform neurofibromas in children with neurofibromatosis type 1.
10. Potential endpoints for assessment of bone health in persons with neurofibromatosis type 1.
11. The Landscape of US and Global Rare Tumor Research Programs: A Systematic Review.
12. Estimated Prevalence, Tumor Spectrum, and Neurofibromatosis Type 1–Like Phenotype of CDKN2A-Related Melanoma-Astrocytoma Syndrome
13. Advancing neurofibromatosis and schwannomatosis clinical trial design: Consensus recommendations from the Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration
14. Potential endpoints for assessment of bone health in persons with neurofibromatosis type 1
15. Supplementary Appendix S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
16. Supplementary Dataset S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
17. Supplementary Table S5 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
18. Supplementary Figure S2 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
19. Data from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
20. Are Some Randomized Clinical Trials Impossible?
21. Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
22. Long-Term Safety and Efficacy of Selumetinib in Children with Neurofibromatosis Type 1 on a Phase 1/2 Trial for Inoperable Plexiform Neurofibromas
23. Data from Isoform- and Phosphorylation-specific Multiplexed Quantitative Pharmacodynamics of Drugs Targeting PI3K and MAPK Signaling in Xenograft Models and Clinical Biopsies
24. Supplementary Materials from Isoform- and Phosphorylation-specific Multiplexed Quantitative Pharmacodynamics of Drugs Targeting PI3K and MAPK Signaling in Xenograft Models and Clinical Biopsies
25. Advancing neurofibromatosis and schwannomatosis clinical trial design: Consensus recommendations from the Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration.
26. Audiometric and Otologic Findings in Children and Young Adults with Neurofibromatosis Type 1 and Plexiform Neurofibromas.
27. Consensus-Based Best Practice Guidelines for the Management of Spinal Deformity and Associated Tumors in Pediatric Neurofibromatosis Type 1: Screening and Surveillance, Surgical Intervention, and Medical Therapy.
28. Audiometric and Otologic Findings in Children and Young Adults with Neurofibromatosis Type 1 and Plexiform Neurofibromas
29. Management of neurofibromatosis type 1-associated plexiform neurofibromas
30. Results of a phase I trial of ganitumab plus dasatinib in patients with rhabdomyosarcoma (RMS).
31. Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity
32. MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus.
33. Using real world data to support regulatory approval of drugs in rare diseases: A review of opportunities, limitations & a case example
34. Isoform- and Phosphorylation-specific Multiplexed Quantitative Pharmacodynamics of Drugs Targeting PI3K and MAPK Signaling in Xenograft Models and Clinical Biopsies
35. Selumetinib for children with neurofibromatosis type 1 and plexiform neurofibromas: A plain language summary of SPRINT.
36. Are Some Randomized Clinical Trials Impossible?
37. Clinical trial design in neurofibromatosis type 1 as a model for other tumor predisposition syndromes
38. Phase II trial of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886 Hydrogen Sulfate) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).
39. Selumetinib in Children with Inoperable Plexiform Neurofibromas
40. Longitudinal evaluation of peripheral nerve sheath tumors in neurofibromatosis type 1: growth analysis of plexiform neurofibromas and distinct nodular lesions
41. The MEK inhibitor selumetinib reduces spinal neurofibroma burden in patients with NF1 and plexiform neurofibromas
42. Reliability of Handheld Dynamometry to Measure Focal Muscle Weakness in Neurofibromatosis Types 1 and 2.
43. Enhancing Neurofibromatosis Clinical Trial Outcome Measures Through Patient Engagement: Lessons From REiNS.
44. A Pediatric Case of Transformed Mycosis Fungoides in a BRCA2 Positive Patient
45. A Pediatric Case of Transformed Mycosis Fungoides in a BRCA2 Positive Patient.
46. SPRINT: Phase II study of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).
47. Association of plexiform neurofibroma volume changes and development of clinical morbidities in neurofibromatosis 1
48. [REiNS] NF Clinical Trials - REiNS Collaboration 2020 Recommendations: Looking Back and Moving Ahead.
49. Plasma and cerebrospinal fluid pharmacokinetics of selumetinib in non-human primates (NHP).
50. Neurofibromatosis Clinical Trials—REiNS Collaboration 2020 Recommendations
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.